# An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

> **NCT02498392** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 161 (actual)

## Conditions studied

- Depressive Disorder
- Anxiety

## Interventions

- **DRUG:** JNJ-42165279
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02498392
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-07
- **Primary completion:** 2019-02-04
- **Final completion:** 2019-02-04
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02498392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02498392, "An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02498392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*